Background: Women's satisfaction with their chosen method of contraception has seldom been evaluated, especially in the primary care setting. This study compared women who use Norplant with those who use oral contraceptives with regard to patient satisfaction with, and the perceived advantages and disadvantages of, their birth control method.
Methods: We sent questionnaires to 115 Norplant users and 148 oral contraceptive users. The questionnaire asked for demographic data; a rating of level of satisfaction with their contraceptive; whether they would choose their method again; whether they would recommend their contraceptive to a friend; and what they perceived as its advantages and disadvantages.
Results: Sixty percent of responding Norplant users were satisfied with their method as compared with 72% of oral contraceptive users (P > .05). Sixty-three percent of Norplant users indicated that they would use their method again, compared with 88% of oral contraceptive users (P < .05). Seventy-four percent of Norplant users said they would recommend their method to a friend as compared with 97% of oral contraceptive users (P < .05). Oral contraceptive users reported significantly less menstrual bleeding and cramping than did Norplant users (P < .05), and Norplant users reported significantly more acne and bleeding irregularities (P < .05).
Conclusions: In our study, the majority of responding Norplant and oral contraceptive users were satisfied with their current method of contraception. However, Norplant users reported being less willing to use their method again or to recommend it to a friend, as compared with women using oral contraceptives. Norplant users noted more bleeding irregularities, more cramping, and increased acne.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Impact of progestin type on the risk of drug interactions between combined oral contraceptives and psychotropic drugs: A pooled analysis of real-world data.
Contraception
December 2024
LVR-University Hospital Essen, Department of Psychiatry and Psychotherapy, Faculty of Medicine, University of Duisburg-Essen, Essen, Germany; Center for Translational Neuro and Behavioral Sciences, University of Duisburg-Essen, Essen, Germany; Bielefeld University, Medical School and University Medical Center OWL, Protestant Hospital of the Bethel Foundation, Department of Psychiatry and Psychotherapy, Bielefeld, Germany.
Objectives: To assess the risk of contraceptive failure and adverse events (AEs) associated with the type of progestin when coadministered with psychotropic drugs within a routine clinical practice setting.
Study Design: A pooled analysis of four large, prospective, multinational cohort studies including women with a new prescription of combined oral contraceptives (COCs) and concomitant psychotropic drug use from 13 European countries and the United States. We determined the frequency of contraceptive failures and AEs within 6 months after COC initiation by progestin type.
Estrogen, progestin, and beyond: thrombotic risk and contraceptive choices.
Hematology Am Soc Hematol Educ Program
December 2024
Division of Hematology and Thromboembolism, Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
Hormonal contraceptive therapy (estrogens and/or progestogens) includes different formulations associated with varying venous thromboembolism (VTE) risks. The thrombogenicity of combined hormonal contraceptives (CHCs) is due at least in part to multiple changes in clotting factors and the vasculature and is dependent on both estrogen dose and type of progestin. Transdermal patch and vaginal ring users have similar or higher VTE risk as combined oral contraceptive users.
View Article and Find Full Text PDFRisk of early etonogestrel and levonorgestrel implant discontinuation in adolescents and adults.
BMC Public Health
November 2024
Department of Obstetrics and Gynecology, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, 1873 Rama IV Road, Patum Wan, Patum Wan, Bangkok, 10330, Thailand.
Article Synopsis
- Etonogestrel and levonorgestrel contraceptive implants are effective for 3 and 5 years, respectively, but early removal before due date can lead to unintended pregnancies, particularly among adolescents.
- A study conducted at King Chulalongkorn Memorial Hospital analyzed early implant discontinuation from 2014 to 2019, finding a 19.3% overall discontinuation rate with intolerance to side effects, like abnormal bleeding, being the main reason for removal.
- Results indicated that adolescents had a lower likelihood of early discontinuation than adults, with factors such as free implants, continuous use, postpartum status, and having children contributing to reduced discontinuation rates.
Abstract: Our objective is to investigate whether infertile women with a history of levonorgestrel intrauterine device (LNG IUD) use have impaired endometrial growth and pregnancy rates after embryo transfer. This is a retrospective cohort study at a single academic medical center of infertile women aged 18-44 with a history of LNG IUD use undergoing their first embryo transfer cycle between January 2019 and January 2021 compared to controls with a history of no prior birth control use (NONE) or prior oral contraceptive (OCP) use. The primary outcome is endometrial thickness prior to embryo transfer.
View Article and Find Full Text PDFFrom policy to practice: Experiences from the ECHO trial following revisions of the WHO medical eligibility criteria for contraceptive use (MEC) guidance on DMPA-IM.
Contracept X
September 2024
UNDP-UNFPA-UNICEF-WHO-World Bank Special Programme of Research, Development and Research Training in Human Reproduction (HRP), World Health Organization, Geneva, Switzerland.
Objectives: In 2017, the World Health Organization (WHO) medical eligibility criteria (MEC) for contraception category for intramuscular depot medroxyprogesterone acetate (DMPA-IM) was changed from MEC category 1 to 2 for women at high risk of HIV acquisition. We assessed the impact of communicating this category change among women in the Evidence for Contraceptive options and HIV Outcomes (ECHO) trial.
Study Design: ECHO was conducted in eSwatini, Kenya, South Africa and Zambia.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!